Soleno Therapeutics reported that its Prader-Willi syndrome drug, Vykat XR, generated estimated net revenues between $31 million and $33 million in Q2 2025, exceeding Wall Street projections. Since the drug’s U.S. approval in March, over 295 physicians have submitted approximately 646 patient ‘start forms’ for therapy initiation. The strong early uptake contrasts with a simultaneous $200 million stock offering aimed at supporting commercialization efforts. Analysts view the sales trajectory as a positive indicator for Soleno, while investor reactions remain cautious amid potential dilution concerns. Vykat XR addresses the insatiable hunger hallmark of Prader-Willi, a rare genetic disorder affecting an estimated 10,000 to 20,000 Americans, representing a significant unmet medical need.